PS
VKTX icon

Principal Securities’s Viking Therapeutics VKTX Stock Holding History

Principal Securities’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-39
Closed -$1.02K – 3440
2025
Q3 		$1.02K Hold
39
– – ﹤0.01% 3401
2025
Q2 		$1.03K Sell
39
-303
-89% -$7.98K ﹤0.01% 3327
2025
Q1 		$13.8K Hold
342
– – ﹤0.01% 2394
2024
Q4 		$13.8K Buy
342
+136
+66% +$7.75K ﹤0.01% 2390
2024
Q3 		$13K Buy
206
+175
+565% +$10.3K ﹤0.01% 2319
2024
Q2 		$1.64K Sell
31
-10
-24% -$656 ﹤0.01% 2964
2024
Q1 		$3.36K Buy
+41
New +$1.82K ﹤0.01% 2728

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Principal Securities's VKTX Position: Q4 2025 in Review

Principal Securities sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 39 shares — an estimated $1.02K sold.

Principal Securities first reported a position in VKTX in Q1 2024 and held it in 7 quarters. The position peaked at $13.8K in Q1 2025. 426 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

  • Principal Securities reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 39 Viking Therapeutics shares in Q4 2025, an estimated $1.02K.
  • Principal Securities first reported a position in Viking Therapeutics in Q1 2024 and held it in 7 quarters.
  • Principal Securities's Viking Therapeutics position peaked at $13.8K in Q1 2025.
  • 426 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.